Bald, Tobias http://orcid.org/0000-0003-0061-235X
Krummel, Matthew F. http://orcid.org/0000-0001-7915-3533
Smyth, Mark J. http://orcid.org/0000-0001-7098-7240
Barry, Kevin C. http://orcid.org/0000-0003-1064-5964
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1173958, 1132519, 1124690)
Cancer Research Institute
Cancer Council Queensland (1140251)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01CA197363, U01CA217864)
Article History
Received: 29 February 2020
Accepted: 4 June 2020
First Online: 20 July 2020
Competing interests
: T.B. has research agreements with ENA Therapeutics and Bristol Myers Squibb and is on the scientific advisory board of Oncomyx. M.F.K. is a founder and shareholder of Pionyr Immunotherapeutics and has research agreements with Bristol Myers Squib, Eli Lilly, Pfizer, Amgen, Abbvie and Genentech. M.J.S. has research agreements with Bristol Myers Squibb and Tizona Therapeutics and is on the scientific advisory board of Tizona Therapeutics and Compass Therapeutics. K.C.B. declares no competing interests.